Exelixis falls 8% on summary for colon cancer candidate zanzalintinib


Colon cancer. A cell that attacks cancer. Colon disease concept. 3d illustration

Mohammed Hanefa Nizamudeen

  • Shares of Exelixis (NASDAQ:Excel) are down ~8% in Wednesday afternoon trading following the release of an executive summary for zanzalintinib in colorectal cancer that included Phase 1 data.
  • The results are from the expanded cohort of the STELLAR-001 trial, in which patients received zanzalintinib



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *